Atyr Pharma Files DEF 14A on Executive Compensation
Ticker: ATYR · Form: DEF 14A · Filed: Mar 19, 2025 · CIK: 1339970
| Field | Detail |
|---|---|
| Company | Atyr Pharma Inc (ATYR) |
| Form Type | DEF 14A |
| Filed Date | Mar 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Atyr Pharma's 2025 DEF 14A is out, detailing 2024 exec pay & equity awards.
AI Summary
Atyr Pharma Inc. filed a DEF 14A on March 19, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, vested, and outstanding, as well as changes in their fair value. Specific dollar amounts and dates related to these awards are presented within the compensation tables.
Why It Matters
This filing provides transparency into how Atyr Pharma compensates its top executives, which can influence investor decisions and perceptions of the company's governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details of executive compensation can sometimes reveal underlying financial health or strategic direction, warranting a medium risk assessment.
Key Numbers
- 2024 — Fiscal Year for Compensation Data (Executive compensation details pertain to this year.)
- 2023 — Prior Fiscal Year for Comparison (Used for comparative analysis of compensation trends.)
Key Players & Entities
- aTYR PHARMA INC (company) — Filer
- 0000950170-25-041992 (filing_id) — Accession Number
- 20250319 (date) — Filing Date
- 1231 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to disclose information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation.
What fiscal year does the executive compensation data primarily cover?
The executive compensation data primarily covers the fiscal year ending December 31, 2024, with comparative data for the fiscal year ending December 31, 2023.
What types of equity awards are detailed in the filing?
The filing details equity awards such as options, restricted stock units (RSUs), and other equity-based compensation, including information on grants, vesting dates, and fair values.
Where is Atyr Pharma Inc. headquartered?
Atyr Pharma Inc. is headquartered at 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121.
What is the SEC file number for Atyr Pharma Inc.?
The SEC file number for Atyr Pharma Inc. is 001-37378.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 19, 2025 regarding aTYR PHARMA INC (ATYR).